SuperworthNeuphoria Therapeutics market cap NEUP
Share price times shares outstanding: what the whole company sells for, since 2022.
- Today, Oct 23, 2026
- $18.6M
- Highest close in our data
- $11.9B
- Oct 2022
Neuphoria Therapeutics is worth $18.6M at the close on Oct 23, 2026, at $3.44 a share.
That is up 27% over the last year.
Its highest close in our data was $11.9B in Oct 2022.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $18.6M | $17.9M | $29.6M | −7% |
| 2025 | $20M | $8.3M | $1.6B | −98% |
| 2024 | $1.2B | $613.1M | $1.7B | −41% |
| 2023 | $2B | $1.4B | $5.8B | −68% |
| 2022 | $6.3B | $6.3B | $11.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Neuphoria Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| NEUPNeuphoria Therapeutics | $18.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| Peer median | $64.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Neuphoria Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.